GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.57M | 8.54M | 8.01M | 7.41M | 7.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.36M | 13.77M | 13.29M | 13.00M | 13.58M |
| Operating Income | -14.36M | -13.77M | -13.29M | -13.00M | -13.58M |
| Income Before Tax | -13.16M | -12.35M | -11.35M | -9.64M | -7.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.16 | -12.35 | -11.35 | -9.64 | -7.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.16M | -12.35M | -11.35M | -9.64M | -7.60M |
| EBIT | -14.36M | -13.77M | -13.29M | -13.00M | -13.58M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -7.01 | -7.48 | -7.72 | -7.04 | -5.61 |
| Normalized Basic EPS | -4.38 | -4.68 | -4.83 | -4.41 | -3.85 |
| EPS Diluted | -7.01 | -7.48 | -7.72 | -7.04 | -5.61 |
| Normalized Diluted EPS | -4.38 | -4.68 | -4.83 | -4.41 | -3.85 |
| Average Basic Shares Outstanding | 7.58M | 6.71M | 5.84M | 5.47M | 5.17M |
| Average Diluted Shares Outstanding | 7.58M | 6.71M | 5.84M | 5.47M | 5.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |